Niclosamide in Pediatric Patients With Relapsed and Refractory AML — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Niclosamide in Pediatric Patients With Relapsed and Refractory AML — Stella

Recruiting

Back to Acute Myeloid Leukemia (AML) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Stanford University, Palo Alto, California

Key details

Phase

Early testing

Sponsor

Stanford University

Collaborators

The Leukemia and Lymphoma Society, Pediatric Cancer Research Foundation (PCRF)

Enrollment target

~16 participants

Started

November 2022

Primary completion

July 2026

Age range

2 Years – 25 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov